Connection

Michael Lilly to Prostatic Neoplasms

Back to Details
This is a "connection" page, showing publications Michael Lilly has written about Prostatic Neoplasms.
Michael Lilly
Connection Strength
3.106
Prostatic Neoplasms
  1. Development of cell-penetrating bispecific antibodies targeting the N-terminal domain of androgen receptor for prostate cancer therapy. Protein Eng Des Sel. 2017 12 01; 30(12):785-793.
    View in: PubMed
    Score: 0.391
  2. A phase II trial of dasatinib in patients with metastatic castration-resistant prostate cancer treated previously with chemotherapy. Anticancer Drugs. 2013 Aug; 24(7):743-53.
    View in: PubMed
    Score: 0.290
  3. Combination therapy of recurrent prostate cancer with the proteasome inhibitor bortezomib plus hormone blockade. Cancer Biol Ther. 2011 Jul 15; 12(2):119-24.
    View in: PubMed
    Score: 0.251
  4. The PIM1 kinase is a critical component of a survival pathway activated by docetaxel and promotes survival of docetaxel-treated prostate cancer cells. J Biol Chem. 2008 Jul 25; 283(30):20635-44.
    View in: PubMed
    Score: 0.201
  5. Gene expression profiling in R-flurbiprofen-treated prostate cancer: R-Flurbiprofen regulates prostate stem cell antigen through activation of AKT kinase. Biochem Pharmacol. 2006 Nov 15; 72(10):1257-67.
    View in: PubMed
    Score: 0.179
  6. Comprehensive Genomic Profiling of Cell-Free DNA in Men With Advanced Prostate Cancer: Differences in Genomic Landscape Based on Race. Oncologist. 2022 Oct 01; 27(10):e815-e818.
    View in: PubMed
    Score: 0.137
  7. Differential Circulating Fungal Microbiome in Prostate Cancer Patients Compared to Healthy Control Individuals. J Immunol Res. 2022; 2022:2574964.
    View in: PubMed
    Score: 0.131
  8. Racial Differences in Patient Portal Activation and Research Enrollment Among Patients With Prostate Cancer. JCO Clin Cancer Inform. 2021 06; 5:768-774.
    View in: PubMed
    Score: 0.125
  9. Financial toxicity and strain among men receiving prostate cancer care in an equal access healthcare system. Cancer Med. 2020 12; 9(23):8765-8771.
    View in: PubMed
    Score: 0.119
  10. Social and clinical determinants of physical activity in prostate cancer survivors. Support Care Cancer. 2021 Jan; 29(1):459-465.
    View in: PubMed
    Score: 0.116
  11. Co-morbidities in a Retrospective Cohort of Prostate Cancer Patients. Ethn Dis. 2020; 30(Suppl 1):185-192.
    View in: PubMed
    Score: 0.115
  12. Comprehensive Analysis of AR Alterations in Circulating Tumor DNA from Patients with Advanced Prostate Cancer. Oncologist. 2020 04; 25(4):327-333.
    View in: PubMed
    Score: 0.112
  13. The Pathologic Role of Toll-Like Receptor 4 in Prostate Cancer. Front Immunol. 2018; 9:1188.
    View in: PubMed
    Score: 0.101
  14. Prostate-specific IL-6 transgene autonomously induce prostate neoplasm through amplifying inflammation in the prostate and peri-prostatic adipose tissue. J Hematol Oncol. 2017 01 11; 10(1):14.
    View in: PubMed
    Score: 0.092
  15. Flavokawain A induces deNEDDylation and Skp2 degradation leading to inhibition of tumorigenesis and cancer progression in the TRAMP transgenic mouse model. Oncotarget. 2015 Dec 08; 6(39):41809-24.
    View in: PubMed
    Score: 0.085
  16. SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol. 2015 May 10; 33(14):1601-8.
    View in: PubMed
    Score: 0.081
  17. Luteolin, ellagic acid and punicic acid are natural products that inhibit prostate cancer metastasis. Carcinogenesis. 2014 Oct; 35(10):2321-30.
    View in: PubMed
    Score: 0.077
  18. Generation of "virtual" control groups for single arm prostate cancer adjuvant trials. PLoS One. 2014; 9(1):e85010.
    View in: PubMed
    Score: 0.075
  19. Plasma-derived exosomal survivin, a plausible biomarker for early detection of prostate cancer. PLoS One. 2012; 7(10):e46737.
    View in: PubMed
    Score: 0.069
  20. Kava components down-regulate expression of AR and AR splice variants and reduce growth in patient-derived prostate cancer xenografts in mice. PLoS One. 2012; 7(2):e31213.
    View in: PubMed
    Score: 0.065
  21. Lycopene enhances docetaxel's effect in castration-resistant prostate cancer associated with insulin-like growth factor I receptor levels. Neoplasia. 2011 Feb; 13(2):108-19.
    View in: PubMed
    Score: 0.061
  22. Differential expression of peroxiredoxins in prostate cancer: consistent upregulation of PRDX3 and PRDX4. Prostate. 2011 May 15; 71(7):755-65.
    View in: PubMed
    Score: 0.060
  23. p53-dependent induction of prostate cancer cell senescence by the PIM1 protein kinase. Mol Cancer Res. 2010 Aug; 8(8):1126-41.
    View in: PubMed
    Score: 0.059
  24. Characterization of a potent and selective small-molecule inhibitor of the PIM1 kinase. Mol Cancer Ther. 2007 Jan; 6(1):163-72.
    View in: PubMed
    Score: 0.046
  25. Pim family kinases enhance tumor growth of prostate cancer cells. Mol Cancer Res. 2005 Aug; 3(8):443-51.
    View in: PubMed
    Score: 0.042
  26. Docetaxel-induced prostate cancer cell death involves concomitant activation of caspase and lysosomal pathways and is attenuated by LEDGF/p75. Mol Cancer. 2009 Aug 28; 8:68.
    View in: PubMed
    Score: 0.014
  27. Novel benzylidene-thiazolidine-2,4-diones inhibit Pim protein kinase activity and induce cell cycle arrest in leukemia and prostate cancer cells. Mol Cancer Ther. 2009 Jun; 8(6):1473-83.
    View in: PubMed
    Score: 0.014
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.